FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Open Access
- 1 January 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (1) , 275-284
- https://doi.org/10.1182/blood-2006-10-053884
Abstract
FTY720 is an immunosuppressant developed to prevent organ transplant rejection. Recent studies indicate an additional role for FTY720 in inducing cell apoptosisKeywords
This publication has 46 references indexed in Scilit:
- FTY720: A Promising Agent for Treatment of Metastatic Hepatocellular CarcinomaClinical Cancer Research, 2005
- FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPaseCancer Letters, 2005
- Bodyguards and assassins: Bcl‐2 family proteins and apoptosis control in chronic lymphocytic leukaemiaImmunology, 2005
- A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2–independent mechanismBlood, 2005
- On the Prediction of the Human Response: A Recycled Mechanistic Pharmacokinetic/Pharmacodynamic ApproachBasic & Clinical Pharmacology & Toxicology, 2005
- Mcl-1 Is a Novel Therapeutic Target for Human SarcomaClinical Cancer Research, 2004
- Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I studyTransplantation, 2003
- A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cellsBritish Journal of Pharmacology, 2003
- Coordinate Involvement of Cell Cycle Arrest and Apoptosis Strengthen the Effect of FTY720Japanese Journal of Cancer Research, 2001
- Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in ratsTransplant Immunology, 1996